Novartis radioligand triumphs in a first-line PhIII trial recruiting patients with rare neuroendocrine tumors

No­var­tis’ ra­di­oli­gand ther­a­py Lu­tathera has hit the pri­ma­ry end­point in a Phase III tri­al in new­ly di­ag­nosed pa­tients with a rare form of neu­roen­docrine tu­mors, lay­ing the foun­da­tion for a po­ten­tial la­bel ex­pan­sion to ear­li­er dis­ease.

In the Phase III NET­TER-2 tri­al, No­var­tis set Lu­tathera plus stan­dard of care oc­treotide ver­sus oc­treotide alone in 222 peo­ple with first-line so­mato­statin re­cep­tor (SSTR)-pos­i­tive gas­troen­teropan­cre­at­ic neu­roen­docrine tu­mors (GEP-NETs).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.